In a new public policy statement on insulin access and affordability released on May 24, 2018, the American Diabetes Association (ADA) recommends increasing transparency across the entire insulin supply chain; streamlining the approval process for biosimilar insulins, lowering or removing patient cost-sharing for insulin and increasing access to health care coverage for all people with diabetes.